RU2015132626A - Мультимодальные наночастицы на основе диоксида кремния - Google Patents
Мультимодальные наночастицы на основе диоксида кремния Download PDFInfo
- Publication number
- RU2015132626A RU2015132626A RU2015132626A RU2015132626A RU2015132626A RU 2015132626 A RU2015132626 A RU 2015132626A RU 2015132626 A RU2015132626 A RU 2015132626A RU 2015132626 A RU2015132626 A RU 2015132626A RU 2015132626 A RU2015132626 A RU 2015132626A
- Authority
- RU
- Russia
- Prior art keywords
- nanoparticles
- nanoparticle
- disease
- hours
- peptide
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims 14
- 239000000377 silicon dioxide Substances 0.000 title claims 6
- 235000012239 silicon dioxide Nutrition 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 9
- 239000002202 Polyethylene glycol Substances 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000007850 fluorescent dye Substances 0.000 claims 5
- 238000012634 optical imaging Methods 0.000 claims 5
- 229920000620 organic polymer Polymers 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 239000013522 chelant Substances 0.000 claims 3
- 125000003827 glycol group Chemical group 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002591 computed tomography Methods 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229920002643 polyglutamic acid Polymers 0.000 claims 2
- -1 polylactate Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000007674 radiofrequency ablation Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000000439 tumor marker Substances 0.000 claims 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 238000000799 fluorescence microscopy Methods 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- CFODQUSMSYDHBS-UHFFFAOYSA-N octreotate Chemical compound O=C1NC(CC=2C=CC=CC=2)C(=O)NC(CC=2[C]3C=CC=CC3=NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(O)=O)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 CFODQUSMSYDHBS-UHFFFAOYSA-N 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 201000001219 parotid gland cancer Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 238000012545 processing Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical group [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/552—Glass or silica
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794414P | 2013-03-15 | 2013-03-15 | |
| US61/794,414 | 2013-03-15 | ||
| US14/215,879 | 2014-03-17 | ||
| PCT/US2014/030401 WO2014145606A1 (en) | 2013-03-15 | 2014-03-17 | Multimodal silica-based nanoparticles |
| US14/215,879 US9999694B2 (en) | 2009-07-02 | 2014-03-17 | Multimodal silica-based nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015132626A true RU2015132626A (ru) | 2017-04-25 |
| RU2015132626A3 RU2015132626A3 (enExample) | 2018-03-23 |
Family
ID=51538041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015132626A RU2015132626A (ru) | 2013-03-15 | 2014-03-17 | Мультимодальные наночастицы на основе диоксида кремния |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9999694B2 (enExample) |
| EP (1) | EP2968621B1 (enExample) |
| JP (1) | JP6412918B2 (enExample) |
| CN (1) | CN105307687A (enExample) |
| AU (1) | AU2014232907B2 (enExample) |
| CA (1) | CA2900363C (enExample) |
| RU (1) | RU2015132626A (enExample) |
| WO (1) | WO2014145606A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733884C1 (ru) * | 2020-01-24 | 2020-10-07 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Нано- и микрочастицы для изоляции специфических субпопуляций экзосом и их анализа |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161734B2 (en) | 2009-07-02 | 2024-12-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| EP3499233A3 (en) | 2009-07-02 | 2019-09-18 | Sloan-Kettering Institute for Cancer Research | Fluorescent silica-based nanoparticles |
| CA2846629C (en) | 2011-08-25 | 2023-08-01 | University Of Central Florida Research Foundation, Inc. | Methods and compositions comprising a c-terminal bax peptide |
| CN105307687A (zh) | 2013-03-15 | 2016-02-03 | 索隆-基特林癌症研究协会 | 多模态的基于二氧化硅的纳米粒子 |
| CN106455979A (zh) | 2013-12-31 | 2017-02-22 | 纪念斯隆-凯特琳癌症中心 | 用于荧光源实时多通道成像的系统、方法和设备 |
| US10111963B2 (en) | 2014-05-29 | 2018-10-30 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016010826A1 (en) | 2014-07-18 | 2016-01-21 | University Of Central Florida Research Foundation, Inc. | Methods and compositions comprising a ct20 peptide |
| WO2016049210A1 (en) * | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Artificial antigen-presenting cells and methods for producing and using the same |
| KR20230042391A (ko) | 2014-10-03 | 2023-03-28 | 나노틱스 엘엘씨 | 가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법 |
| US9968688B2 (en) | 2014-11-12 | 2018-05-15 | Verily Life Sciences Llc | Shielded targeting agents, methods, and in vivo diagnostic system |
| KR20170094268A (ko) | 2014-12-15 | 2017-08-17 | 메모리얼 슬로안-케터링 캔서 센터 | 향상된 신경-결합 선택성을 갖는 고리형 펩티드, 상기 고리형 펩티드와 결합된 나노입자, 및 실시간 생체내 신경 조직 영상화를 위한 이들의 용도 |
| WO2016134474A1 (en) * | 2015-02-25 | 2016-09-01 | London Health Sciences Centre Research Inc. | Automated segmentation of histological sections for vasculature quantification |
| BR112017020689A2 (en) * | 2015-04-07 | 2018-06-26 | Memorial Sloan-Kettering Cancer Center | nanoparticulate immunoconjugates |
| WO2016176462A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| US10209242B2 (en) | 2015-05-21 | 2019-02-19 | Emit Imaging, Inc. | Fluorescence histo-tomography (FHT) systems and methods |
| US10736972B2 (en) | 2015-05-29 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
| JP6975131B2 (ja) * | 2015-07-23 | 2021-12-01 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | ボリュームイメージの対話型平面スライスからの内視鏡誘導 |
| WO2017040671A1 (en) * | 2015-08-31 | 2017-03-09 | Invicro, Llc | Fluorescence histo-tomography (fht) systems and methods |
| EP3165153A1 (en) | 2015-11-05 | 2017-05-10 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | System for fluorescence aided surgery |
| BR112018010205A2 (pt) * | 2015-11-20 | 2018-11-21 | Cristal Delivery B V | nanopartículas com direcionamento ativo |
| KR20180093961A (ko) | 2015-12-15 | 2018-08-22 | 메모리얼 슬로안-케터링 캔서 센터 | 조직 구별, 예를 들어, 수술 중 시각화를 위한 영상화 시스템 및 방법 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| US20180369422A1 (en) * | 2015-12-31 | 2018-12-27 | City Of Hope | Nanoparticles for cancer detection |
| WO2017176762A1 (en) | 2016-04-06 | 2017-10-12 | Nanotics, Llc | Particles comprising subparticles or nucleic acid scaffolds |
| KR20190003630A (ko) * | 2016-04-29 | 2019-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 악성 뇌 종양에서의 표적화된 입자 침투, 분포, 및 반응을 위한 조성물 및 방법 |
| CN109475279A (zh) * | 2016-07-07 | 2019-03-15 | 纪念斯隆凯特琳癌症中心 | 用于颗粒驱动的、基于知识的且预测性癌症放射基因组学的成像系统和方法 |
| CA3040257A1 (en) | 2016-07-14 | 2018-01-18 | University Of Central Florida Research Foundation, Inc. | Bi-dota complex-loaded dendritic polymer nanoparticles |
| WO2018035519A1 (en) * | 2016-08-19 | 2018-02-22 | Amrita Vishwa Vidyapeetham | Compositions and methods for autoimmune disease treatment |
| JP6793290B2 (ja) * | 2016-09-30 | 2020-12-02 | 学校法人甲南学園 | 被験物質の皮膚感作性の評価方法、及び樹脂固定ペプチド |
| WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| US11306187B2 (en) * | 2017-02-21 | 2022-04-19 | Research & Business Foundation Sungkyunkwan University | Polymer-iron oxide nano-complex, uses thereof and preparation method thereof |
| CN110891613B (zh) * | 2017-04-07 | 2022-08-26 | 观点医疗有限公司 | 多模式成像标记物 |
| US12397067B2 (en) * | 2017-04-10 | 2025-08-26 | Cornell University | Sulfur- or heavy atom-containing nanoparticles, methods of making same, and uses thereof |
| WO2018213851A1 (en) | 2017-05-19 | 2018-11-22 | Cornell University | Functionalized nanoparticles and methods of making and using same |
| EP3634500B1 (en) * | 2017-05-25 | 2023-10-25 | Memorial Sloan-Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
| WO2018237253A1 (en) | 2017-06-23 | 2018-12-27 | Memorial Sloan Kettering Cancer Center | Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye. |
| CN107589085B (zh) * | 2017-08-16 | 2020-03-31 | 广西师范大学 | 一种用适配体调控纳米二氧化硅活性-吸收光谱测定Hg2+的方法 |
| CN107607502B (zh) * | 2017-08-30 | 2019-10-01 | 江苏大学 | 一种利用多色荧光碳点同时且可视化检测多种抗生素的方法及多种抗生素的荧光检测指示卡 |
| WO2019059379A1 (ja) * | 2017-09-21 | 2019-03-28 | 国立大学法人北海道大学 | 生体検査装置及び生体検査方法 |
| WO2019113004A1 (en) | 2017-12-04 | 2019-06-13 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
| JP7296589B2 (ja) * | 2017-12-05 | 2023-06-23 | Jsr株式会社 | 親水化色素含有粒子、色素含有粒子、親水化色素含有粒子の製造方法および生体内を観察する方法 |
| WO2019142913A1 (ja) * | 2018-01-18 | 2019-07-25 | 国立大学法人東京大学 | ３次元組織内のグルコース濃度マッピングのための蛍光マイクロ粒子 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| KR102806143B1 (ko) * | 2018-05-01 | 2025-05-14 | 프레드 허친슨 캔서 센터 | 유전자 발현을 위한 나노입자 및 이의 용도 |
| EP3787684A1 (en) | 2018-05-02 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Nanotherapeutic systems and methods using particle-driven photodynamic therapy (pdt) |
| WO2019213456A1 (en) | 2018-05-02 | 2019-11-07 | Cornell University | Ultrasmall nanoparticles and methods of making, using and analyzing same |
| WO2019213458A1 (en) * | 2018-05-02 | 2019-11-07 | Cornell University | Inorganic nanophotosensitizers and methods of making and using same |
| EP3811054A1 (en) * | 2018-06-21 | 2021-04-28 | Codiak BioSciences, Inc. | Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering |
| US11172903B2 (en) * | 2018-08-01 | 2021-11-16 | Uih America, Inc. | Systems and methods for determining kinetic parameters in dynamic positron emission tomography imaging |
| WO2020051032A1 (en) * | 2018-09-07 | 2020-03-12 | The Regents Of The University Of California | Sealable, mesoporous silica shell nanoreactor |
| IL282213B2 (en) | 2018-10-16 | 2025-07-01 | Silicycle Inc | A tunable process for the preparation and use of silica capsules/spheres |
| WO2020081642A1 (en) * | 2018-10-16 | 2020-04-23 | University Of North Texas Health Science Center | Process for engineering targeted nanoparticles |
| CN111317829B (zh) * | 2018-12-14 | 2022-07-19 | 复旦大学附属肿瘤医院 | 一种spect/fi双模态分子影像探针及其制备方法 |
| US12313629B2 (en) * | 2019-03-20 | 2025-05-27 | Biosquare Inc. | Standard material composition for verifying bioanalyzer and standard strip using same |
| CN110101292A (zh) * | 2019-05-16 | 2019-08-09 | 珠海格力电器股份有限公司 | 米饭烹饪控制方法、装置、存储介质和电饭煲 |
| WO2020252215A1 (en) * | 2019-06-12 | 2020-12-17 | Cellfe, Inc. | Methods and systems for cell labeling and imaging |
| CN114929152B (zh) | 2019-08-28 | 2025-03-25 | 观点医疗有限公司 | 超声标记物检测、标记物及相关联的系统、方法和物品 |
| CN110551497B (zh) * | 2019-09-15 | 2022-06-10 | 四川农业大学 | 一种分子印迹量子点磷光探针的制备方法及其应用 |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| ES2827327B2 (es) * | 2019-11-20 | 2022-05-12 | Univ Valencia Politecnica | Sistema teranostico para difusion dirigida a celulas cancerosas de agentes terapeuticos y de imagen |
| US11903767B2 (en) | 2019-11-27 | 2024-02-20 | View Point Medical, Inc. | Composite tissue markers detectable via multiple detection modalities |
| US11882992B2 (en) | 2019-11-27 | 2024-01-30 | View Point Medical, Inc. | Composite tissue markers detectable via multiple detection modalities including radiopaque element |
| CA3163311A1 (en) * | 2019-12-31 | 2021-07-08 | Nai-Kong V. Cheung | Multimodal fluorine-cy3/5/7-dota-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy |
| JP2023518902A (ja) * | 2020-03-27 | 2023-05-08 | イグザカ フランス | 標的化ポリ（β－アミノエステル） |
| WO2021252448A1 (en) * | 2020-06-10 | 2021-12-16 | Memorial Sloan Kettering Cancer Center | Imaging compounds selective for nav1.7 |
| AU2021370647A1 (en) | 2020-10-27 | 2023-06-08 | Elucida Oncology, Inc. | Folate receptor targeted nanoparticle drug conjugates and uses thereof |
| CN114182358A (zh) * | 2021-10-28 | 2022-03-15 | 西北工业大学 | 一种抗tau蛋白荧光多肽纳米颗粒阵列、制备方法及用途 |
| US20250049730A1 (en) * | 2021-11-24 | 2025-02-13 | The Curators Of The University Of Missouri | Ultra small gelatin nanoparticles, composite structures and synthesis method |
| CN114308153B (zh) * | 2021-12-17 | 2023-06-02 | 华南农业大学 | 一种用于检测那非类物质的固相萃取微流控芯片及用于检测那非类物质的系统 |
| WO2023181025A1 (en) * | 2022-03-22 | 2023-09-28 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Peptide-based phosphate binder for the treatment of hyperphosphatemia |
| JP2025519441A (ja) * | 2022-06-06 | 2025-06-26 | サンテック メディカル，インコーポレイティド | 心血管疾患を標的とする複合体 |
| CN115575625B (zh) * | 2022-10-17 | 2025-08-08 | 济宁学院 | 新型四氧化三铁荧光纳米探针的制备方法及应用 |
| WO2024142933A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立研究開発法人物質・材料研究機構 | 蛍光色素標識粒子を含む組織マーキング剤 |
| WO2024168323A2 (en) * | 2023-02-09 | 2024-08-15 | Cornell University | Methods of cellular imaging and inorganic nanoimaging agents for same |
| WO2024168291A2 (en) * | 2023-02-09 | 2024-08-15 | Cornell University | Nanoparticles for imaging and treatment of arthritis and inflammatory joint diseases |
| WO2024220548A2 (en) * | 2023-04-17 | 2024-10-24 | University Of Southern California | Molecular-mri using ccr2-targeted micelles for detection of lymph node metastases |
| KR20250128235A (ko) * | 2024-02-20 | 2025-08-27 | 주식회사 심비스타 | Nmda 수용체 항체 및 형광물질을 포함하는 신규 테라그노스틱 나노복합체 및 이것의 용도 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6344272B1 (en) | 1997-03-12 | 2002-02-05 | Wm. Marsh Rice University | Metal nanoshells |
| GB2330907A (en) | 1997-10-28 | 1999-05-05 | Applied Imaging Int Ltd | A karyotyper and methods for producing karyotypes |
| CA2318779C (en) | 1998-01-22 | 2009-08-25 | Luminex Corporation | Microparticles with multiple fluorescent signals |
| US6428811B1 (en) | 1998-03-11 | 2002-08-06 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
| US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
| US7279150B2 (en) | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| US20030219785A1 (en) * | 2002-02-01 | 2003-11-27 | Vanderbilt University | Targeted drug delivery methods |
| US8620410B2 (en) * | 2002-03-12 | 2013-12-31 | Beth Israel Deaconess Medical Center | Multi-channel medical imaging system |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| US20080102036A1 (en) * | 2003-06-04 | 2008-05-01 | Poss Kirtland G | Biocompatible Fluorescent Silicon Nanoparticles |
| WO2006042233A1 (en) | 2004-10-08 | 2006-04-20 | The Cleveland Clinic Foundation | Medical imaging using quantum dots |
| US7653427B2 (en) * | 2004-11-12 | 2010-01-26 | Intra-Medical Imaging LLC | Method and instrument for minimally invasive sentinel lymph node location and biopsy |
| RU2007138027A (ru) | 2005-03-14 | 2009-04-20 | Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) | Биоактивные пептиды fus-1 и комплексы полипептидов с наночастицами |
| US20070065359A1 (en) | 2005-03-14 | 2007-03-22 | Shiladitya Sengupta | Nanocells for diagnosis and treatment of diseases and disorders |
| US8084001B2 (en) | 2005-05-02 | 2011-12-27 | Cornell Research Foundation, Inc. | Photoluminescent silica-based sensors and methods of use |
| US7601355B2 (en) | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| WO2007002540A2 (en) | 2005-06-24 | 2007-01-04 | Kung Hank F | Radiolabeled-pegylation of ligands for use as imaging agents |
| FR2888753B1 (fr) | 2005-07-21 | 2008-04-04 | Commissariat Energie Atomique | Vecteur cible avec fonction d'imagerie activable |
| EP1973575B1 (en) | 2005-12-22 | 2019-07-24 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| WO2008044138A1 (en) | 2006-10-12 | 2008-04-17 | Syddansk Universitet | Optical nanosensor for detection of reactive oxygen species |
| WO2008049118A2 (en) * | 2006-10-19 | 2008-04-24 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s) |
| US7902332B2 (en) | 2006-11-30 | 2011-03-08 | General Electric Company | Fluorine-labeled compounds |
| US20080213377A1 (en) | 2006-12-08 | 2008-09-04 | Bhatia Sangeeta N | Delivery of Nanoparticles and/or Agents to Cells |
| US8062215B2 (en) | 2007-04-13 | 2011-11-22 | Ethicon Endo-Surgery, Inc. | Fluorescent nanoparticle scope |
| EP1995327A1 (en) | 2007-05-21 | 2008-11-26 | Humboldt Universität zu Berlin | Probe for detecting a particular nucleic acid sequence |
| CN101903290B (zh) * | 2007-08-31 | 2013-01-09 | 混合硅晶科技公司 | Peg包覆的核-壳二氧化硅纳米颗粒及其制备方法和应用 |
| DE102007052517A1 (de) | 2007-10-29 | 2009-04-30 | Autoimmun Diagnostika Gmbh | ELISPOT-Verfahren mit zwei Filtersystemen |
| US8968699B2 (en) * | 2007-11-15 | 2015-03-03 | The Regents Of The University Of California | Switchable nano-vehicle delivery systems, and methods for making and using them |
| CN101918816B (zh) | 2007-12-21 | 2015-12-02 | 哈佛大学 | 三维中的亚衍射极限图像分辨率 |
| US8389679B2 (en) * | 2009-02-05 | 2013-03-05 | The Regents Of The University Of California | Targeted antimicrobial moieties |
| WO2010121064A2 (en) | 2009-04-15 | 2010-10-21 | Cornell Research Foundation, Inc. | Improved fluorescent silica nanoparticles through silica densification |
| EP3499233A3 (en) | 2009-07-02 | 2019-09-18 | Sloan-Kettering Institute for Cancer Research | Fluorescent silica-based nanoparticles |
| US20130017265A1 (en) | 2009-12-16 | 2013-01-17 | Massachusetts Institute Of Technology | Particles for multiple agent delivery |
| GB201121288D0 (en) | 2011-12-12 | 2012-01-25 | Univ Muenster Wilhelms | Functionalised silicon nanoparticles |
| US9006987B2 (en) | 2012-05-07 | 2015-04-14 | Lighting Science Group, Inc. | Wall-mountable luminaire and associated systems and methods |
| EP2863952B1 (en) | 2012-06-22 | 2018-09-12 | Cornell University | Mesoporous oxide nanoparticles and methods of making and using same |
| WO2014011973A2 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-ras-selective lethal compounds and their use |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| JP6568802B2 (ja) | 2013-02-20 | 2019-08-28 | コーネル ユニバーシティＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ | 多層蛍光性ナノ粒子及びその製造並びに使用方法 |
| CN105307687A (zh) | 2013-03-15 | 2016-02-03 | 索隆-基特林癌症研究协会 | 多模态的基于二氧化硅的纳米粒子 |
| CN106455979A (zh) | 2013-12-31 | 2017-02-22 | 纪念斯隆-凯特琳癌症中心 | 用于荧光源实时多通道成像的系统、方法和设备 |
| US10111963B2 (en) | 2014-05-29 | 2018-10-30 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
| WO2016015044A1 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Biopolymer-nanoparticle composite implant for tumor cell tracking |
| EP3029032A1 (en) * | 2014-12-05 | 2016-06-08 | Centre National de la Recherche Scientifique (CNRS) | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof |
| KR20170094268A (ko) | 2014-12-15 | 2017-08-17 | 메모리얼 슬로안-케터링 캔서 센터 | 향상된 신경-결합 선택성을 갖는 고리형 펩티드, 상기 고리형 펩티드와 결합된 나노입자, 및 실시간 생체내 신경 조직 영상화를 위한 이들의 용도 |
| BR112017020689A2 (en) | 2015-04-07 | 2018-06-26 | Memorial Sloan-Kettering Cancer Center | nanoparticulate immunoconjugates |
| CA2985083A1 (en) | 2015-05-04 | 2016-11-10 | Cornell University | Ultrasmall nanoparticles and methods of making and using same |
| US10736972B2 (en) | 2015-05-29 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
| US20180296595A1 (en) | 2015-09-11 | 2018-10-18 | Memorial Sloan Kettering Cancer Center | Methods and compositions for cancer treatment |
| WO2018102372A1 (en) | 2016-11-30 | 2018-06-07 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
| US12397067B2 (en) | 2017-04-10 | 2025-08-26 | Cornell University | Sulfur- or heavy atom-containing nanoparticles, methods of making same, and uses thereof |
| WO2018213851A1 (en) | 2017-05-19 | 2018-11-22 | Cornell University | Functionalized nanoparticles and methods of making and using same |
| EP3630089A4 (en) | 2017-05-24 | 2021-06-09 | Ferro Therapeutics, Inc. | PROCEDURE FOR CANCER THERAPY |
| EP3634500B1 (en) | 2017-05-25 | 2023-10-25 | Memorial Sloan-Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
| WO2018237253A1 (en) | 2017-06-23 | 2018-12-27 | Memorial Sloan Kettering Cancer Center | Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye. |
| WO2019113004A1 (en) | 2017-12-04 | 2019-06-13 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
-
2014
- 2014-03-17 CN CN201480016246.6A patent/CN105307687A/zh active Pending
- 2014-03-17 CA CA2900363A patent/CA2900363C/en active Active
- 2014-03-17 AU AU2014232907A patent/AU2014232907B2/en active Active
- 2014-03-17 JP JP2016503393A patent/JP6412918B2/ja active Active
- 2014-03-17 US US14/215,879 patent/US9999694B2/en active Active
- 2014-03-17 RU RU2015132626A patent/RU2015132626A/ru not_active Application Discontinuation
- 2014-03-17 WO PCT/US2014/030401 patent/WO2014145606A1/en not_active Ceased
- 2014-03-17 EP EP14763612.0A patent/EP2968621B1/en active Active
-
2017
- 2017-09-25 US US15/714,189 patent/US10039847B2/en active Active
-
2018
- 2018-06-15 US US16/009,267 patent/US10548998B2/en active Active
-
2019
- 2019-12-13 US US16/714,182 patent/US11419955B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733884C1 (ru) * | 2020-01-24 | 2020-10-07 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Нано- и микрочастицы для изоляции специфических субпопуляций экзосом и их анализа |
Also Published As
| Publication number | Publication date |
|---|---|
| US10039847B2 (en) | 2018-08-07 |
| BR112015020782A2 (pt) | 2017-10-10 |
| EP2968621A1 (en) | 2016-01-20 |
| EP2968621B1 (en) | 2022-08-10 |
| RU2015132626A3 (enExample) | 2018-03-23 |
| AU2014232907A1 (en) | 2015-08-20 |
| US20180093000A1 (en) | 2018-04-05 |
| AU2014232907B2 (en) | 2017-12-21 |
| CA2900363C (en) | 2023-10-10 |
| US20200376149A1 (en) | 2020-12-03 |
| JP6412918B2 (ja) | 2018-10-24 |
| WO2014145606A9 (en) | 2015-04-16 |
| CN105307687A (zh) | 2016-02-03 |
| US20140248210A1 (en) | 2014-09-04 |
| EP2968621A4 (en) | 2016-11-16 |
| WO2014145606A1 (en) | 2014-09-18 |
| CA2900363A1 (en) | 2014-09-18 |
| US9999694B2 (en) | 2018-06-19 |
| US11419955B2 (en) | 2022-08-23 |
| US20180326103A1 (en) | 2018-11-15 |
| US10548998B2 (en) | 2020-02-04 |
| JP2016516729A (ja) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015132626A (ru) | Мультимодальные наночастицы на основе диоксида кремния | |
| JP2016516729A5 (enExample) | ||
| US20240082408A1 (en) | Bilirubin nanoparticle, use thereof, and preparation method therefor | |
| Liu et al. | Nanotechnology for cancer imaging: advances, challenges, and clinical opportunities | |
| JP4936312B2 (ja) | 新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム | |
| US9889199B2 (en) | PSMA ligands and uses thereof | |
| JP6789823B2 (ja) | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 | |
| CN102533248B (zh) | 荧光纳米探针及其制备方法 | |
| JP5531332B2 (ja) | 新規な分子集合体、それを用いた分子イメージング用分子プローブ及び薬剤搬送システム用分子プローブ、並びに分子イメージングシステム及び薬剤搬送システム | |
| Alberti | From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy | |
| RU2009119451A (ru) | Контрастные вещества для детекции рака предстательной железы | |
| Chen et al. | Multifunctional electrospinning composite fibers for orthotopic cancer treatment in vivo | |
| US20210100920A1 (en) | Methods and agents for the detection and treatment of cancer | |
| Joshi et al. | Near-infrared-labeled peptide multimer functions as phage mimic for high affinity, specific targeting of colonic adenomas in vivo (with videos) | |
| Niki et al. | Optimization of dendrimer structure for sentinel lymph node imaging: Effects of generation and terminal group | |
| US10117956B2 (en) | Radiolabeled active targeting pharmaceutical composition and the use thereof | |
| CN105412950B (zh) | 具有mri/spect双模态影像肿瘤靶向多功能纳米探针及制备和应用 | |
| Tang et al. | Nanoprobe-mediated precise imaging and therapy of glioma | |
| JP6602034B2 (ja) | 標的化分子およびその使用 | |
| WO2013158719A1 (en) | Use of non-metallic cest agents for mri monitoring of nanoparticle delivery | |
| CN104288786A (zh) | 基于近红外量子点的肿瘤靶向诊疗系统及其制备方法 | |
| Chen et al. | Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model | |
| CN116271223B (zh) | 一种基于生物素-亲和素系统的耦合外泌体的水凝胶的制备方法和应用 | |
| CN103275722B (zh) | 一种磁光双模态成像探针稀土纳米微粒及其制法和用途 | |
| CN117065054A (zh) | 一种多模态造影剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180723 |